Nurix Therapeutics
NRIX
195 hedge funds and large institutions have $1.81B invested in Nurix Therapeutics in 2026 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 67 increasing their positions, 43 reducing their positions, and 26 closing their positions.
1,567% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $237K
65% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 26
56% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 43
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
7% more funds holding
Funds holding: 182 → 195 (+13)
16% less capital invested
Capital invested by funds: $2.15B → $1.81B (-$338M)
34.35% less ownership
Funds ownership: 147.52% → 113.17% (-34%)
Top Buyers
| 1 |
VPC
Vestal Point Capital
New York
|
+$30M |
| 2 |
State Street
Boston,
Massachusetts
|
+$26.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.7M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$14.8M |
| 5 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$9.33M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$45.8M |
| 2 |
GA
General Atlantic
New York
|
-$13.2M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$12.9M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$12.3M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.5M |
NRIX Hedge Fund Activity: Q1 2026 in Review
195 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2026, worth a combined $1.81B — down 16% from $2.15B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new NRIX positions and 26 closed out — a net gain of 17 holders — while 67 added to existing stakes and 43 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $30M. The largest seller was Point72 Asset Management, cutting an estimated $45.8M.
- 195 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2026, up from 182 in Q4 2025.
- Funds reported $1.81B of Nurix Therapeutics stock for Q1 2026, down 16% quarter-over-quarter.
- 43 funds opened new Nurix Therapeutics positions in Q1 2026 and 26 closed out, a net change of +17 holders.
- The largest Nurix Therapeutics buyer in Q1 2026 was Vestal Point Capital, an estimated $30M added.
- The largest Nurix Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $45.8M sold.
Based on aggregated 13F filings for Q1 2026.